-
公开(公告)号：US11672854B2
公开(公告)日：2023-06-13
申请号：US16980838
申请日：2019-01-16
发明人： Hyun Joo Youn , Eun Yeong Han
IPC分类号： A61K39/145 , A61P31/16 , C12N15/86 , C07K14/005 , A61K39/00
CPC分类号： A61K39/145 , A61P31/16 , C07K14/005 , C12N15/86 , A61K2039/543 , A61K2039/552 , A61K2039/70
摘要： The present invention relates to a multivalent live influenza vaccine platform using a recombinant adenovirus. The present invention is a live attenuated vaccine platform using a recombinant virus and it is easy to inoculate because it is infected with the respiratory tract like influenza virus and exhibits a vaccine action and it is a multivalent vaccine which combines two types into one and it is a highly novel vaccine that does not need to mix viruses compared to vaccines using multiple combinations of one vaccine. The present invention is the first vaccine in which a gene obtained by fusion of two influenza antigen genes into one gene is incorporated into a recombinant virus. Instead of using the entire HA gene of influenza, but using a structurally independent HA1 gene, which is about half of the total HA gene, several types of HA genes could be fused into one. When the recombinant virus was inoculated into mice by nasal inhalation, it was confirmed that it is an effective vaccine in which the vaccine effect is induced by two inoculations, and the vaccine platform of the present invention is expected to be useful for the development of a vaccine for human influenza infection.
-
公开(公告)号：US11603409B2
公开(公告)日：2023-03-14
申请号：US16620530
申请日：2018-06-05
发明人： Hyun Joo Youn
IPC分类号： C07K16/28 , A61P35/00 , A61K35/17 , A61K38/17 , A61K39/395 , C07K14/725 , C07K14/705 , A61K39/00 , A61K33/243 , A61K31/353 , A61K31/5377
摘要： The present invention relates to a humanized DR4 antibody gene having apoptosis-inducing activity, and a dual-acting chimeric antigen receptor T cell or natural killer cell therapeutic agent, a secretory DR4 scFv antibody recombinant protein synthesized by using a humanized DR4 scFv antibody gene (humanized anti-DR4 scFv) may be used as an anticancer drug specifically targeting DR4 by binding to DR4 expressed on surface of the cancer cells to induce apoptosis of the cancer cells. In addition, the chimeric antigen receptor (CAR) using the humanized DR4 scFv antibody gene is predicted to have a strong anticancer immune effect as a dual-acting cell therapeutic agent, which is capable of simultaneously inducing apoptosis in cancer cells by DR4 and exhibiting a cytotoxic effect for cytotoxic T lymphocytes or natural killer cells by binding to DR4 expressed on the surface of cancer cells, as a DR4-specific CAR-T cell or CAR-NK cell therapeutic agent.
-
搜索结果
2 条记录 (耗时 0.015 秒)
